Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · technology

Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery

3 November 2026 · By · Wire by Fusion42

Published

3 November 2026

Topic

technology

◆ Sectors

Drug DiscoveryGenerative AIBiotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 3 November 2026 · Fusion42 review

Variational AI has entered a collaboration with Merck to apply generative AI techniques to the discovery and development of novel small molecule therapeutics targeting two specific targets selected by Merck.

This Wire brief sits within Fusion42's coverage of Drug Discovery, Generative AI and Biotech.

◆ ◆ The Wire takeaway

Generative AI is now directly shaping drug discovery outputs with big pharma like Merck backing specific targets. You can start pitching your AI drug design tools now or prepare for Merck and similar firms snapping up proven AI platforms.

◆ Coverage

1 source · 3 Nov 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryGenerative AIBiotechgenerative-aidrug-discoverybiotech-collaborationsmall-moleculespharma-ai